Latest news with #S.aureus
Hindustan Times
14-06-2025
- Health
- Hindustan Times
7 best menstrual cup sterilizers to level up your period hygiene
Switching to a menstrual cup is a sustainable choice but keeping it clean is just as important as choosing the right one. Proper sterilization isn't just about hygiene, it is about protecting your intimate health every cycle. Boiling your cup in a pan might work, but let's be honest, it's messy and inconvenient. This is where a menstrual cup sterilizer comes in. From compact steamers to portable UV devices, these smart gadgets are designed to make your period routine safer, cleaner, and stress-free. In this guide, we have highlighted the best menstrual cup sterilizers to help you simplify hygiene without compromising on care. Steeping menstrual cups in boiled water for 5 minutes after washing with soap or water effectively eliminates S. aureus, suggesting a safer, simpler alternative to continuous boiling between periods (International Journal of Environmental Research and Public Health). However, to make things simpler for you, we have selected the top-rated menstrual cup sterilizers that you can try: Sterilize your menstrual cup effortlessly in just 3 minutes with the Sirona Steam Sterilizer. This BPA-free menstrual cup sterilizer uses high-temperature steam to kill 99.9% of germs without the use of detergent or boiling. Simply plug it in, add water, and let it do the work. Its automatic shut-off ensures safety, and its compact design makes it perfect for discreet storage between cycles. Sirona Menstrual Cup Sterilizer | Clean your Period Cup Effortlessly | Kills 99% of Germs in 3 Minutes with Steam | BPA Free | Automatic Power-Off | 1 Unit,White Skip the stove and clean your cup the smart way with Pee Safe's Steam Sterilizer. This compact, BPA-free menstrual cup sterilizer kills 99.9% of germs in just 3-5 minutes and auto shuts off when done. Ideal for menstrual cups, discs, or kegel balls, it offers a no-mess, no-fuss solution to period hygiene. Plug it in, add water, and relax, your hygiene is sorted. Pee Safe Menstrual Cup Steam Sterilizer | Clean Your Cup With Ease | Kills 99.9% Germs in 3 Minutes with Steam | White, For women, BPA Free & Auto Power Cut-Off This 2-in-1 steamer and kit from YTYOMUR comes with two reusable medical-grade silicone menstrual cups and an adorable egg-shaped sterilizer. One-button operation, high-temperature steam, and compatibility with most cup brands make it an efficient, travel-friendly cleaner. The steamer doubles as a storage case and offers a quick, 3-minute clean, which makes this menstrual cup sterilizer ideal for women who want an all-in-one hygiene solution on the go. YTYOMUR Menstrual Cup Steamer Sterilizer with 2 Reusable Period Cups, Menstrual Cups Cleaner Wash Kit, One Button Control Automatic High Temperature Steam Sterilization for Women Feminine Hygiene Care Get a complete hygiene solution with Pee Safe's combo of a soft, reusable menstrual cup and a steam sterilizer. The cup offers 12 hours of leak-free comfort, while the menstrual cup sterilizer makes cleaning quick and safe in just 5 minutes. Together, they reduce the risk of rashes and infections, making your period eco-friendly, economical, and worry-free. Pee Safe Menstrual Cups For Women | Medium Size With Menstrual Cup Sterilizer | Clean Your Menstrual Cup Hassle Free In Just 5 Minutes, Kills 99.9% Of Germs Azah's advanced steam sterilizer ensures 99.9% germ removal in just 3 minutes, increasing your cup's lifespan while protecting your intimate health. Designed for use at home or while travelling, this menstrual cup sterilizer in India doubles as a discreet storage case. With BPA-free silicone and auto shut-off, it is a safe and eco-conscious way to keep your cup clean. ALSO READ: 10 top-rated sunscreens for dry skin that protect without causing dryness Azah Menstrual Cup Sterilizer | Portable Sterilizer for Menstrual Cup for Women & Girls | Clean Your Cup With Ease | Kills 99.9% Germs in 3 Minutes with Steam | BPA Free & Auto Power Cut-Off SAFECUP brings you a no-kitchen-needed sterilizing solution, just plug it into your bedroom or bathroom. It heats to 100°C and steams your cup clean in 5 minutes. Designed with a mesh base so your cup never touches the bottom, and featuring auto shut-off for worry-free use, this menstrual cup sterilizer encourages regular cleaning. Plus, it comes with a 1-year warranty for added confidence. SAFECUP Menstrual Cup Sterilizer for women, Clean Your Period Cup In a Hygenic Way,Automatic Switch Off,No Risk Of Melting Cup, Plug it in Room or Bathroom, No Kitchen/No Vessels,Pack of 1 piece,Pink Pure Ella's microwave-safe sterilizer is a collapsible, BPA-free silicone cup designed for effortless cleaning. Just add water and microwave your menstrual cup for 2 minutes. It folds flat for compact storage and comes with a discreet bag, making it ideal for travel. You can also use boiling water directly for steaming if a microwave isn't available. Pure Ella Menstrual Cup Sterilizer - Microwave Safe, Collapsible and BPA Free Silicone Period Cup Cleaner - Ecofriendly Feminine Hygiene ● Rinse the cup: Wash your menstrual cup with mild soap and water to remove any residue. ● Add water: Pour the recommended amount of clean water (usually 5–10 ml) into the menstrual cup sterilizer. ● Place the cup: Insert the cup upside down inside the best menstrual sterilizer in India. ● Cover and start: Close the lid, plug in the device and start the sterilization. ● Auto shut-off or cool down: Now, wait for the auto shut-off or let it cool after microwaving. • Ready to use: Once cool, your cup is sterilized and ready for use or storage. Best pickleball paddles for low-impact exercises: Get fit without joint pain with our top 8 picks Menstrual Hygiene Day: 10 must-have period products for a stain and stress-free cycle Best biotin supplements in India (2025): 8 trusted picks to fight hair fall naturally You should sterilize your menstrual cup before and after every menstrual cycle. Daily rinsing during your period is enough, but deep cleaning ensures hygiene. Yes! Microwave sterilizers are a safe and effective alternative. Just add water, place the cup inside, and microwave for 2-3 minutes with the lid loosely closed. Yes, daily sterilization is safe if done properly. Steam sterilizers don't damage medical-grade silicone and can actually help extend your cup's hygiene and life. If there's no auto shut-off, monitor the process manually. Unplug after 3-5 minutes to prevent overheating. Always check the product manual for exact timing and safety tips. Disclaimer: At Hindustan Times, we help you stay up-to-date with the latest trends and products. Hindustan Times has an affiliate partnership, so we may get a part of the revenue when you make a purchase. We shall not be liable for any claim under applicable laws, including but not limited to the Consumer Protection Act, 2019, with respect to the products. The products listed in this article are in no particular order of priority.
Yahoo
04-05-2025
- Health
- Yahoo
Fungi on Your Skin Could Produce a Potent Antibiotic to Fight Infections
A deadly superbug that sometimes claims the lives of more than a million people globally a year may have a nemesis that lives right under your nose. Quite literally. It dominates your skin microbiome, where it seems to keep staph infections at bay. The overlooked agent is a species of natural yeast, called Malassezia sympodialis – one of the most prevalent microorganisms on healthy human skin. New research suggests that as it cleans oil and fat from your body's exterior, the fungi can produce a fatty acid that stops the development and growth of a staph infection. According to lab experiments, led by scientists at the University of Oregon (UO), M. sympodialis can antagonize Staphylococcus aureus bacteria through its acidic byproducts. Because the yeast-produced acid is often present in healthy skin, researchers think it stops S. aureus from over-colonizing the microbiome. S. aureus is a normal component of the skin microbiome, but if it takes over, or if it penetrates the tissue or bloodstream, it can seed dangerous infections. Skin and soft tissue infections involving result in approximately 500,000 hospitalizations annually in the United States, and the bacterium is capable of becoming resistant to every class of antibiotics we currently have in our arsenal. This means new drug therapies must be continuously put forward to stay ahead of its deadly toll. The fact that our skin microbiome has natural defenses against staph infections is worth exploring further. "There are lots of studies that identify new antibiotic structures," says lead author and evolutionary biologist Caitlin Kowalski from UO, "but what was fun and interesting about ours is that we identified (a compound) that is well-known and that people have studied before." The compound in question is called 10-hydroxy palmitic acid (10-HP), and in the past, scientists probably overlooked its antimicrobial powers because it only unleashes its toxic effects in a low pH environment, like the skin, and not under normal lab conditions. Using human skin biopsies from healthy donors, Kowalski and colleagues found the acid was produced by resident Malassezia yeast. "It was like finding a needle in a haystack but with molecules you can't see," says Kowalski's adviser, biologist Matthew Barber. In the lab, Barber, Kowalski, and their colleagues tested how M. sympodialis yeast impacts various strains of S. aureus. After two hours of the yeast treatment, most S. aureus strains showed greater than a 100-fold reduction in viability. Over time, S. aureus strains developed some resistance to M. sympodialis' 10-HP, and the dangerous bacteria did so in a similar way to how they develop tolerance to clinical antibiotics. Interestingly, researchers found that other species of Staphylococcus bacteria, which do not pose the same threat as S. aureus, had already figured out similar ways to coexist with the M. sympodialis yeast. "Given the prevalence of Malassezia within the mammalian skin microbiota, we are likely just scratching the surface of its roles in shaping microbial interactions and colonization resistance in this niche," write the authors. Kowalski is now planning to do a deep dive into the genetic mechanisms of antibiotic-resistant staph infections to better understand how the bacteria rapidly mutates to avoid a whole range of antimicrobial agents. "We still have a lot of work to do in understanding the microorganisms, and also finding new ways that we can possibly treat or prevent those infections," says Barber. The study was published in Current Biology. The First Synthetic 'Mini Prion' Could Help Study Diseases Like Alzheimer's Here's Why You Should Try 'Jeffing' to Run Longer And Farther Childhood Adversity May Damage The Brain's White Matter, Study Finds
Jordan News
26-02-2025
- Health
- Jordan News
A Common Mistake That Could Contaminate Your Toothbrush with Germs - Jordan News
Dr. Samuel Choudhury, a resident doctor in Singapore, revealed a common mistake many people make when using their toothbrush without realizing its potential health risks. اضافة اعلان In a video posted on Instagram, Choudhury explained that placing your toothbrush near the toilet exposes it to bacteria, viruses, and even airborne fecal particles. He explained that flushing the toilet can cause bacteria to rise up to 6 feet (about 1.83 meters) in the air, making the toothbrush vulnerable to these contaminants if placed near the toilet. He emphasized that simply using a toothbrush cover doesn't protect it. In fact, it could increase bacteria growth due to the humid environment it creates. Choudhury referenced a 2015 study on toothbrushes in student dorms, which found that 60% of them were contaminated with fecal matter, highlighting the widespread nature of the issue. He further explained that plastic covers, which many people believe protect their toothbrushes, may actually increase the risk of bacteria growth instead of preventing it. To protect your toothbrush from contamination, Choudhury offered some practical advice: Store the toothbrush vertically to ensure proper drainage of water and reduce moisture buildup. Replace the toothbrush or its head every 3 to 4 months to maintain cleanliness and effectiveness. Keep the toothbrush away from the toilet and close the lid when flushing to prevent airborne particles from spreading. Store the toothbrush in a well-ventilated area to allow it to dry quickly, reducing bacteria growth. As for UV sterilizers or mouthwash cleaning, Choudhury noted that these are not entirely necessary if the basic steps are followed. This warning comes after scientific studies highlighted that flushing the toilet releases microscopic droplets containing bacteria such as E. coli and S. aureus, which can cause gastrointestinal infections or respiratory diseases if inhaled. Dr. Wajid Ali, a researcher at the China University of Earth Sciences, confirmed that improving bathroom ventilation systems and strengthening exhaust fans can reduce the concentration of these particles in the air, contributing to public health protection.
Associated Press
17-02-2025
- Business
- Associated Press
LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7
ZURICH--(BUSINESS WIRE)--Feb 17, 2025-- , a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participants have been vaccinated in a Phase 1 controlled study of its multivalent vaccine candidate, LBT-SA7. The candidate is designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen Staphylococcus aureus ( S. aureus). In this context, the company also announced the award of US$6.5 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance the clinical development of LBT-SA7. S. aureus infections pose a significant global health challenge, causing an estimated 1 million deaths annually. Notably, 90% of all community-acquired S. aureus infections are SSTIs. The absence of a vaccine to prevent S. aureus, coupled with only limited treatment options - particularly against multidrug-resistant strains of the pathogen, often described as methicillin-resistant S. aureus (MRSA) - highlights the urgent need for effective preventive solutions. LimmaTech's vaccine candidate, LBT-SA7, is the first multivalent vaccine entirely based on secreted antigens to address this critical need. LBT-SA7 contains weakened forms of the pathogen's toxins, referred to as toxoids, designed to prevent infections by neutralizing the toxins secreted by S. aureus. This approach offers a promising solution to combat the widespread bacterial threat. LimmaTech started a Phase 1 clinical trial ( NCT06719219) in the U.S. after receiving a Fast Track designation from the U.S. Food and Drug Administration (FDA). This first-in-human study aims to evaluate the safety and immunogenicity of LBT-SA7 against S. aureus. It is a randomized, double-blinded, and controlled dose-escalation study expected to enroll 130 healthy adults aged 18-50 years. Initial results are anticipated in the second half of 2025. 'Developing an S. aureus vaccine has long been a significant scientific challenge,' explained Dr. Patricia Martin-Killias, Chief Operating Officer of LimmaTech. 'We believe LBT-SA7 has the potential to provide a much-needed solution for those suffering from S. aureus infections. We are excited to launch the first-in-human clinical trial for LBT-SA7, bringing us closer to addressing an urgent global health challenge.' 'We are grateful for the significant support from CARB-X, which is not only instrumental in accelerating the clinical development of our S. aureus vaccine candidate LBT-SA7 but also underscores the importance of our mission to develop efficient solutions for preventing microbial infections and protecting from their threatening consequences for affected people,' added Dr. Franz-Werner Haas, Chief Executive Officer of LimmaTech. Research reported in this press release is supported by CARB-X. CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), Germany's Federal Ministry of Education and Research (BMBF), and the UK Department of Health and Social Care as part of the Global Antimicrobial Resistance Innovation Fund (GAMRIF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. About Staphylococcus aureus Staphylococcus aureus ( S. aureus), a Gram-positive bacterial pathogen, affects approximately 30% of the human population while causing a spectrum of infections, from SSTI to severe conditions like pneumonia and bloodstream infections. S. aureus is the leading cause of antimicrobial resistance (AMR)-attributed fatalities with community-acquired and hospital-acquired infections being the most prevalent. SSTIs caused by S. aureus range from mild to severe and entail microbial invasion into the skin layers and underlying soft tissues. Traditional antibiotic treatments, both oral therapy and intravenous administration reserved for severe cases, have become increasingly less effective due to the rise of antibiotic resistance. S. aureus has been designated as a 'high priority' pathogen by the World Health Organization (WHO), underscoring the urgency for innovative vaccine approaches and effective treatment strategies. About LimmaTech Biologics AG LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide. LimmaTech Biologics is backed by specialist healthcare investors, including Adjuvant Capital, AXA IM Alts, Novo Holdings REPAIR Impact Fund, and Tenmile. For more information, please visit Franz-Werner Haas, CEO For media enquiries Jacob Verghese or Anja Heuer Trophic Communications Phone: +49 151 7441 6179 KEYWORD: SWITZERLAND EUROPE SOURCE: LimmaTech Biologics AG Copyright Business Wire 2025. PUB: 02/17/2025 04:00 AM/DISC: 02/17/2025 04:02 AM
Yahoo
17-02-2025
- Health
- Yahoo
LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7
CARB-X awards LimmaTech US$6.5 million to advance clinical development of LBT-SA7 ZURICH, February 17, 2025--(BUSINESS WIRE)--LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participants have been vaccinated in a Phase 1 controlled study of its multivalent vaccine candidate, LBT-SA7. The candidate is designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen Staphylococcus aureus (S. aureus). In this context, the company also announced the award of US$6.5 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance the clinical development of LBT-SA7. S. aureus infections pose a significant global health challenge, causing an estimated 1 million deaths annually. Notably, 90% of all community-acquired S. aureus infections are SSTIs. The absence of a vaccine to prevent S. aureus, coupled with only limited treatment options - particularly against multidrug-resistant strains of the pathogen, often described as methicillin-resistant S. aureus (MRSA) - highlights the urgent need for effective preventive solutions. LimmaTech's vaccine candidate, LBT-SA7, is the first multivalent vaccine entirely based on secreted antigens to address this critical need. LBT-SA7 contains weakened forms of the pathogen's toxins, referred to as toxoids, designed to prevent infections by neutralizing the toxins secreted by S. aureus. This approach offers a promising solution to combat the widespread bacterial threat. LimmaTech started a Phase 1 clinical trial (NCT06719219) in the U.S. after receiving a Fast Track designation from the U.S. Food and Drug Administration (FDA). This first-in-human study aims to evaluate the safety and immunogenicity of LBT-SA7 against S. aureus. It is a randomized, double-blinded, and controlled dose-escalation study expected to enroll 130 healthy adults aged 18-50 years. Initial results are anticipated in the second half of 2025. "Developing an S. aureus vaccine has long been a significant scientific challenge," explained Dr. Patricia Martin-Killias, Chief Operating Officer of LimmaTech. "We believe LBT-SA7 has the potential to provide a much-needed solution for those suffering from S. aureus infections. We are excited to launch the first-in-human clinical trial for LBT-SA7, bringing us closer to addressing an urgent global health challenge." "We are grateful for the significant support from CARB-X, which is not only instrumental in accelerating the clinical development of our S. aureus vaccine candidate LBT-SA7 but also underscores the importance of our mission to develop efficient solutions for preventing microbial infections and protecting from their threatening consequences for affected people," added Dr. Franz-Werner Haas, Chief Executive Officer of LimmaTech. Research reported in this press release is supported by CARB-X. CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), Germany's Federal Ministry of Education and Research (BMBF), and the UK Department of Health and Social Care as part of the Global Antimicrobial Resistance Innovation Fund (GAMRIF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. About Staphylococcus aureus Staphylococcus aureus (S. aureus), a Gram-positive bacterial pathogen, affects approximately 30% of the human population while causing a spectrum of infections, from SSTI to severe conditions like pneumonia and bloodstream infections. S. aureus is the leading cause of antimicrobial resistance (AMR)-attributed fatalities with community-acquired and hospital-acquired infections being the most prevalent. SSTIs caused by S. aureus range from mild to severe and entail microbial invasion into the skin layers and underlying soft tissues. Traditional antibiotic treatments, both oral therapy and intravenous administration reserved for severe cases, have become increasingly less effective due to the rise of antibiotic resistance. S. aureus has been designated as a "high priority" pathogen by the World Health Organization (WHO), underscoring the urgency for innovative vaccine approaches and effective treatment strategies. About LimmaTech Biologics AG LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide. LimmaTech Biologics is backed by specialist healthcare investors, including Adjuvant Capital, AXA IM Alts, Novo Holdings REPAIR Impact Fund, and Tenmile. For more information, please visit View source version on Contacts LimmaTech Biologics AG Franz-Werner Haas, CEOE-Mail: media@ For media enquiries Jacob Verghese or Anja HeuerTrophic CommunicationsPhone: +49 151 7441 6179Email: limmatech@ Sign in to access your portfolio
